ArticleMediators of inflammation2017
Th1/Th17-Related Cytokines and Chemokines and Their Implications in the Pathogenesis of Pemphigus Vulgaris.
Article in Mediators of inflammation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04096222 (Comparative Analysis of the Th17 Cellular Response in Active and Inactive Pemphigus Vulgaris Patients), which is not on this map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparative Analysis of the Th17 Cellular Response in Active and Inactive Pemphigus Vulgaris Patients
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.
- Risk of Incident Venous Thromboembolism Among Patients With Bullous Pemphigoid or Pemphigus Vulgaris: A Nationwide Cohort Study With Meta-Analysis.Journal of the American Heart Association · 2023Pooled it
- Rituximab remodels the circulating immune landscape in pemphigus vulgaris revealed by high-dimensional immune profiling.Journal of translational autoimmunity · 2026Article
- Targeting IL-33 and TSLP: A Novel Approach to Modulate Type 2 and Non-Type 2 Inflammatory Pathways in Pemphigus Vulgaris.Clinical reviews in allergy & immunology · 2026Review
- Osteoporosis in Pemphigus: Steroids Are Not the Only Story.Dermatology practical & conceptual · 2026Article
- Unraveling the autoimmune architecture of pemphigus: from B-cell depletion to network-based immune engineering.Frontiers in immunology · 2026Review
- Venous thromboembolism in bullous pemphigoid: current evidence from an updated systematic review.Dermatology reports · 2025Article
- The Role of Microbiota in the Pathogenesis of Bullous Pemphigoid and Pemphigus Vulgaris: Evidence, Controversies, and Perspectives.International journal of molecular sciences · 2025Review
- Crosstalk Between Keratinocytes and T Cells in Ulcerative Oral Mucosal Diseases: Mechanisms of Epithelial Dysfunction and Therapeutic Perspectives.Journal of inflammation research · 2025Review
- JAK-STAT pathway, type I/II cytokines, and new potential therapeutic strategy for autoimmune bullous diseases: update on pemphigus vulgaris and bullous pemphigoid.Frontiers in immunology · 2025Review
- High dietary acid load predicts severity of autoimmune skin disease: a cross-sectional study.Scientific reports · 2024Article
- Review
- Impact of Pemphigus on Sleep Quality: A Prospective Observational Single-Center Case-Control Study.Dermatology practical & conceptual · 2024Article
- Article
- Cytokine profiling reveals HLA-linked Th2 and Th17 driven immune activation in pemphigus vulgaris patients and genetically susceptible healthy controls.Frontiers in immunology · 2024Article
- Healthy individuals genetically at-risk for the development of Pemphigus vulgaris or Alopecia areata share disease-like cytokine dysregulation.Frontiers in immunology · 2024Article
- Causal effects of autoimmune diseases on temporomandibular disorders and the mediating pathways: a Mendelian randomization study.Frontiers in immunology · 2024Article
- Cut-off values for IL-21 and IL-23 as biochemical markers for pemphigus vulgaris.Journal of medicine and life · 2023Article
- Article
- Pemphigus vulgaris following second dose of mRNA-(Pfizer-BioNTech) COVID-19 vaccine.Dermatologic therapy · 2022Article
- Elevated Serum Levels of Interleukin-15 in Pemphigus Vulgaris Patients: a Potential Therapeutic Target.Dermatology practical & conceptual · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pemphigus vulgaris (PV) is an autoimmune disease characterized by the presence of IgG autoantibodies against desmoglein-3. Despite the variety of findings, the chemokine and cytokine profiles that characterize the immune response in the disease are still poorly explored. Thus, 20 PV patients and 20 controls were grouped according to gender, ethnicity, place of residence, and clinical parameters of the disease. Then, the levels of chemokines and of Th1/Th2/Th17/Treg/Th9/Th22-related cytokines were assessed in the serum. PV patients had higher levels of inflammatory Th1/Th17 cytokines (IFN-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.